etomoxir has been researched along with crizotinib in 1 studies
Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (crizotinib) | Trials (crizotinib) | Recent Studies (post-2010) (crizotinib) |
---|---|---|---|---|---|
260 | 8 | 93 | 1,780 | 112 | 1,718 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bianchetti, E; Bruce, JN; Canoll, P; Humala, N; Karpel-Massler, G; Kleiner, G; Mahajan, A; Mela, A; Nguyen, TTT; Quinzii, CM; Sanchez-Quintero, MJ; Shang, E; Shu, C; Siegelin, MD; Torrini, C; Westhoff, MA; Zhang, Y; Zhao, J | 1 |
1 other study(ies) available for etomoxir and crizotinib
Article | Year |
---|---|
MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carnitine; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Crizotinib; Drug Synergism; Epoxy Compounds; Fatty Acids; Gene Expression Profiling; Glioblastoma; Glycolysis; Guanidines; Humans; Lactams, Macrocyclic; Metabolomics; Mice; Mitochondria; Mitochondrial Dynamics; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Proteomics; Proto-Oncogene Proteins c-met; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |